Our study also confirms the link between CD8+ TILs and CD274 expression in stage II–III colon carcinoma and supports the idea that upregulation of CD274 in colorectal carcinoma may be a result of an adaptive immune response, which may have prognostic value and be a therapeutic target for PD-1/PD-L1 immunotherapy. The gene discussed is CD8A; the disease is colon carcinoma.